BioGene Therapeutics to Participate in the 43rd JP Morgan Healthcare Conference
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has announced that its subsidiary BioGene Therapeutics will participate in the 43rd JP Morgan Healthcare Conference from January 13-16, 2025, in San Francisco.
The company's leadership team attending includes Dr. Harry Parekh (Chief Research Officer & Scientific Founder), along with board members Dr. Deepak Sampath, Steve Glover, and Patroski J. Lawson. BioGene, under parent company PreveCeutical, focuses on developing innovative preventive and curative therapies using organic and nature-identical products.
CEO Stephen Van Deventer emphasized the importance of having their Scientific Founder and experienced team members present to showcase their accomplishments and future plans. Interested parties can request meetings with the team via info@biogenetherapeutics.com.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) ha annunciato che la sua filiale BioGene Therapeutics parteciperà alla 43ª Conferenza Sanitaria JP Morgan dal 13 al 16 gennaio 2025, a San Francisco.
Il team di leadership della società che parteciperà include Dr. Harry Parekh (Chief Research Officer e Fondatore Scientifico), insieme ai membri del consiglio Dr. Deepak Sampath, Steve Glover e Patroski J. Lawson. BioGene, sotto la compagnia madre PreveCeutical, si concentra sulla sviluppo di terapie innovative preventive e curative utilizzando prodotti organici e identici alla natura.
Il CEO Stephen Van Deventer ha sottolineato l'importanza di avere il loro Fondatore Scientifico e membri esperti del team presenti per mostrare i loro traguardi e i piani futuri. Le parti interessate possono richiedere incontri con il team all'indirizzo info@biogenetherapeutics.com.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) ha anunciado que su filial BioGene Therapeutics participará en la 43.ª Conferencia de Salud JP Morgan del 13 al 16 de enero de 2025, en San Francisco.
El equipo de liderazgo de la empresa que asistirá incluye al Dr. Harry Parekh (Director de Investigación y Fundador Científico), junto con los miembros de la junta Dr. Deepak Sampath, Steve Glover y Patroski J. Lawson. BioGene, bajo la empresa matriz PreveCeutical, se centra en el desarrollo de terapias innovadoras preventivas y curativas utilizando productos orgánicos e idénticos a la naturaleza.
El CEO Stephen Van Deventer enfatizó la importancia de contar con su Fundador Científico y miembros experimentados del equipo presentes para mostrar sus logros y planes futuros. Las partes interesadas pueden solicitar reuniones con el equipo a través de info@biogenetherapeutics.com.
프리뷰시쿨 메디컬 Inc. (CSE: PREV) (OTCQB: PRVCF)는 자회사인 바이오진 테라퓨틱스가 2025년 1월 13일부터 16일까지 샌프란시스코에서 열리는 제43회 JP 모건 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다.
참석할 회사의 리더십 팀에는 해리 파레크 박사 (최고 연구 책임자 및 과학적 창립자)와 이사인 딥락 샘팟 박사, 스티브 글로버, 패트로스키 J. 로손이 포함됩니다. 바이오진은 모회사인 프리뷰시쿨 아래에서 유기적이고 자연과 동일한 제품을 사용하여 혁신적인 예방 및 치료 요법을 개발하는 데 주력하고 있습니다.
CEO 스티븐 반 드벤터는 그들의 과학적 창립자와 경험이 풍부한 팀원들이 참석하여 그들의 성과와 향후 계획을 보여주는 것이 중요하다고 강조했습니다. 관심 있는 분들은 info@biogenetherapeutics.com을 통해 팀과의 회의를 요청할 수 있습니다.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) a annoncé que sa filiale BioGene Therapeutics participera à la 43e Conférence Sanitaire JP Morgan du 13 au 16 janvier 2025, à San Francisco.
Le comité de direction de la société qui assistera comprend Dr. Harry Parekh (Directeur de la recherche et Fondateur scientifique), avec les membres du conseil Dr. Deepak Sampath, Steve Glover et Patroski J. Lawson. BioGene, sous la société mère PreveCeutical, se concentre sur le développement de thérapies préventives et curatives innovantes utilisant des produits organiques et identiques à la nature.
Le PDG Stephen Van Deventer a souligné l'importance d'avoir leur Fondateur scientifique et des membres expérimentés de l'équipe présents pour mettre en valeur leurs réalisations et leurs plans futurs. Les parties intéressées peuvent demander des réunions avec l'équipe à l'adresse info@biogenetherapeutics.com.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) hat bekanntgegeben, dass ihre Tochtergesellschaft BioGene Therapeutics an der 43. JP Morgan Gesundheitskonferenz vom 13. bis 16. Januar 2025 in San Francisco teilnehmen wird.
Das Führungsteam der Firma, das teilnehmen wird, umfasst Dr. Harry Parekh (Chief Research Officer und Wissenschaftlicher Gründer), zusammen mit den Vorstandsmitgliedern Dr. Deepak Sampath, Steve Glover und Patroski J. Lawson. BioGene, unter der Muttergesellschaft PreveCeutical, konzentriert sich auf die Entwicklung innovativer präventiver und heilender Therapien mit organischen und naturidentischen Produkten.
CEO Stephen Van Deventer betonte die Wichtigkeit, ihren wissenschaftlichen Gründer und erfahrenen Teammitglieder anwesend zu haben, um ihre Errungenschaften und zukünftigen Pläne zu präsentieren. Interessierte Parteien können über info@biogenetherapeutics.com Meetings mit dem Team anfordern.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - January 7, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. today announced its participation in the upcoming 43rd JP Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, CA.
BioGene's leadership team, including Dr. Harry Parekh (Chief Research Officer & Scientific Founder), Dr. Deepak Sampath (Board Member), Steve Glover (Board Member), and Patroski J. Lawson (Board Member), will be attending the conference and participating in meetings.
If there is any interest in meeting with our team, please send us your information to info@biogenetherapeutics.com.
Stephen Van Deventer, CEO of BioGene, commented:
"Having our Scientific Founder and highly experienced team members at the JP Morgan Conference will be of great value in showcasing the work we have accomplished and intend to further this coming year."
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
About BioGene Therapeutics Inc.
BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's
On Behalf of the Board of Directors,
PreveCeutical Medical Inc. & BioGene Therapeutics Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer
For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding receipt of regulatory and other consents and approvals for the Acquisition; PreveCeutical, PreveCeutical Australia, and BioGene completing the Acquisition as contemplated by the Agreement; PreveCeutical receiving the necessary regulatory and other consents and approvals for the Distribution; and PreveCeutical completing the Distribution as contemplated above. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company; regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene; the Company's failure to obtain the required consents and approvals for the Acquisition and the Distribution; and the Company determining that the Distribution is not an optimal strategy following tax and business consultations. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236289
FAQ
When and where is BioGene Therapeutics (PRVCF) presenting at the JP Morgan Healthcare Conference 2025?
Which key executives from PRVCF will attend the 2025 JP Morgan Healthcare Conference?
How can investors arrange meetings with BioGene Therapeutics at the JP Morgan Healthcare Conference?
What is the relationship between BioGene Therapeutics and PreveCeutical Medical (PRVCF)?
What type of healthcare solutions does PRVCF develop?
